Lambert-eaton myasthenic syndrome

被引:7
|
作者
Weimer, Maria B. [1 ]
Wong, Joaquin [1 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70118 USA
关键词
CELL LUNG-CANCER; NEUROMUSCULAR-TRANSMISSION; INTRAVENOUS IMMUNOGLOBULIN; AUTOIMMUNE DISORDERS; 3,4-DIAMINOPYRIDINE; DIAGNOSIS; THERAPY; PYRIDOSTIGMINE; GUANIDINE; DISEASES;
D O I
10.1007/s11940-009-0010-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Lambert Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disease. Often, the signs and symptoms of LEMS are mistaken for myasthenia gravis and therefore the workup is misdirected. A physician must look for an occult malignancy when the diagnosis is made and then continue to search for a malignancy for at least 5 years after diagnosis. The diagnosis of LEMS can be confirmed with electrophysiologic studies or with serum calcium channel antibodies. In most patients with LEMS, 3,4-diaminopyridine will improve strength. In patients without malignancy, immunosuppressants do have a role in the treatment of LEMS. Patients and physicians must be aware that certain situations and drugs may exacerbate weakness.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [31] CONGENITAL LAMBERT-EATON MYASTHENIC SYNDROME
    BADY, B
    CHAUPLANNAZ, G
    CARRIER, H
    ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1985, 61 (03): : S85 - S85
  • [32] Retropulsion in Lambert-Eaton myasthenic syndrome
    Sonoo, M.
    Hatanaka, Y.
    Higashihara, M.
    Takeda, K.
    Fukutake, T.
    Imafuku, I.
    Mikata, T.
    Shimizu, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S139 - S139
  • [33] Treatment for Lambert-Eaton myasthenic syndrome
    Maddison, P
    Newsom-Davis, J
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):
  • [34] Seronegative Lambert-Eaton myasthenic syndrome
    Nakao, YK
    Motomura, M
    Fukudome, T
    Fukuda, T
    Shiraishi, H
    Yoshimura, T
    Tsujihata, M
    Eguchi, K
    NEUROLOGY, 2002, 59 (11) : 1773 - 1775
  • [35] Lambert-Eaton myasthenic syndrome in childhood
    Kostera-Pruszczyk, A.
    Ryniewicz, B.
    Rowinska-Marcinska, K.
    Dutkiewicz, M.
    Kaminska, A.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (02) : 194 - 196
  • [36] Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome
    Oh, Shin J.
    JOURNAL OF CLINICAL NEUROLOGY, 2024, 20 (04): : 353 - 361
  • [37] The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands
    Wirtz, PW
    van Dijk, JG
    van Doorn, PA
    van Engelen, BGM
    van der Kooi, AJ
    Kuks, JB
    Twijnstra, A
    de Visser, M
    Visser, LH
    Wokke, JH
    Wintzen, AR
    Verschuuren, JJ
    NEUROLOGY, 2004, 63 (02) : 397 - 398
  • [38] The role of autoantibodies in Lambert-Eaton myasthenic syndrome
    Lang, B
    Waterman, S
    Pinto, A
    Jones, D
    Moss, F
    Boot, J
    Brust, P
    Williams, M
    Stauderman, K
    Harpold, M
    Motomura, M
    Moll, JW
    Vincent, A
    Newsom-Davis, J
    MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 : 596 - 605
  • [39] Prostate carcinoma and the Lambert-Eaton myasthenic syndrome
    Delahunt, B
    Abernethy, DA
    Johnson, CA
    Nacey, JN
    JOURNAL OF UROLOGY, 2003, 169 (01): : 278 - 279
  • [40] Lambert-Eaton myasthenic syndrome and prostatic adenocarcinoma
    Monteiro, Cecilia
    Moreira, Isabel
    Lima, Jose Lopes
    Santos, Ernestina
    NEUROLOGICAL SCIENCES, 2015, 36 (11) : 2145 - 2146